Smartest Doc
Novartis drug Gilenya shows long-term efficacy and safety according to new data from extension of phase III head-to-head study Full Text
Novartis, 06/12/2012
New long–term data for Gilenya (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment. These results, from an extension of the phase III head–to–head TRANSFORMS study, also showed improved efficacy for patients switched to Gilenya from Avonex (interferon–beta–1a IM), a commonly prescribed MS treatment.
